Some ICI responses were seen in patients with high tumor mutation load (TMB) and/or high PD-L1 expression by IHC, both of which are markers of response to immunotherapy, but other patients with low TMB and PD-L1 negativity still responded (120–124). This evidence concerns the gene CD274 and neoplasm.